The plates that emerge from the kitchen are not exactly smaller. However, more is being left on them by the tables. There is a skipping of starters. More often than not, the dessert menu is courteously waived. You might not notice it because it’s so subtle. However, the owners of these eateries have.
One of the more surprising factors to affect British hospitality in recent years has been the rise of GLP-1 drugs, such as Ozempic, Wegovy, and Mounjaro. These medications, which were first created to treat Type 2 diabetes, have been shown to significantly suppress appetite, reduce cravings for sugary and fatty foods, and, in certain situations, lessen the desire for alcohol. According to PwC research, between three and seven million people in the UK are currently using them, which could account for 10% of the population once the recently approved oral tablet becomes widely available.
It is not a specialized health trend. That represents a structural change in the way a sizable portion of the British public views food.
Storekit, a hospitality tech company, has released some startling data. The share of orders for the decadent staples that once dominated high-street menus—burgers, fries, and milkshakes—has decreased from about 19% to less than 9%. Soups have increased by 186%, bowl-based dishes by 143%, and low-alcohol or non-alcoholic beverages by 344% during the same time frame. Mocktails have increased by 190%. These are not slight changes. These are indicators.
It’s possible that GLP-1 medications aren’t the only cause of this. Even before Ozempic became well-known, there was a growing demand for lighter, higher-protein foods and general wellness trends. However, the timing coincides in ways that seem more than coincidental, and the acceleration in the numbers is difficult to ignore.
The average order value hasn’t collapsed, which is intriguing and possibly counterintuitive. Customers taking these drugs typically place smaller orders, but they seem to be spending the same amount—or sometimes more—on better ingredients and more thoughtful selections. Many of these patrons seem to view eating out as more of a ritual than an act of indulgence. Fewer things, but more thoughtful ones.
Restaurants’ reactions have been inconsistent, as expected. Venues at the higher end have made deliberate moves. In Berkshire, Heston Blumenthal’s The Fat Duck debuted a “Mindful Experience” menu. A smaller, “exquisite bites” tasting format was introduced by London’s Otto’s for patrons seeking something sophisticated without the scope of a full tasting menu. Rather than being marketing gimmicks, these seem like real adaptations.
Mid-market companies and chains are also discreetly experimenting. Protein bowls and “Build Your Own” salads are becoming more popular. Menus that did not use that format in the past are starting to include flexible small-plate sections. The direction of travel is constant whether operators are actively responding to GLP-1 users or are just following what the data indicates.
The extent of this is still unknown. Research indicates that many GLP-1 users maintain at least some of the eating habits they formed while taking the drug, and a sizable portion of them eventually stop taking it. If that’s the case, even the inactive patrons might be having a long-lasting impact on how British eateries approach menu design and portion sizes.
The pandemic, the smoking ban, and the squeeze on living expenses have all had a greater impact on the hospitality sector. However, those disruptions were evident and happened right away. It’s quieter this time. Order patterns are shifting, people’s attitudes toward alcohol are changing, and diners are leaving half of their main course on the plate because they truly don’t need any more, not because it wasn’t good. For an industry that is based on the enjoyment of excess, that presents a different kind of challenge.
FAQs
Are Ozempic and Wegovy changing what people order in British restaurants?
Yes — lighter dishes, protein bowls, and alcohol-free drinks are rising sharply while burgers and fries decline.
How many people in the UK are using GLP-1 drugs like Ozempic and Wegovy?
Between three and seven million UK adults — roughly 10% of the population.
Are restaurants losing revenue because of Ozempic users eating less?
Not really — users order less but spend more on premium dishes, keeping order values stable.
Which drinks trends are linked to the rise of weight-loss jabs in the UK?
Low/no-alcohol drinks are up 344% and mocktails up 190%, as GLP-1 drugs reduce alcohol cravings.
How are British restaurants adapting to smaller appetites?
Many are introducing smaller tasting menus, protein-forward dishes, and flexible small-plate formats.
